AngioDynamics (ANGO) Q1 2026 Earnings Transcript

Core Insights - AngioDynamics reported a strong performance in the first quarter of fiscal year 2026, with a revenue increase of 12.2% to $75.7 million, driven by growth in both Med Tech and Med Device segments [15][4][5] - The Med Tech segment saw significant growth of 26.1%, while the Med Device segment grew by 2.3% [15][16] - The company is focused on strategic transformation, emphasizing profitability alongside revenue growth, and plans to continue investing in product development and regulatory opportunities [4][5][28] Financial Performance - Total revenue for Q1 FY 2026 was $75.7 million, a 12.2% increase compared to the same quarter in FY 2025 [15] - Med Tech revenue reached $35.3 million, reflecting a 26.1% year-over-year growth, while Med Device revenue was $40.4 million, up 2.3% [15][16] - Gross margin improved to 55.3%, a 90-basis-point increase from the previous year, driven by pricing initiatives and a favorable sales mix [19][20] Segment Highlights - The Auryon platform generated $16.5 million in revenue, growing 20.1% year-over-year, marking 17 consecutive quarters of double-digit growth [17] - Mechanical Thrombectomy revenue, including AngioVac and AlphaVac, increased by 41.2% year-over-year, totaling $11.3 million [18] - NanoKnife revenue was $6.4 million, a 26.7% increase, with expectations for continued growth driven by increased adoption in prostate cancer treatment [10][18] Strategic Initiatives - The company is expanding its sales force for Mechanical Thrombectomy, increasing dedicated sales representatives from 40 to 50 to support growth [39] - AngioDynamics is focused on enhancing its product portfolio and market penetration, particularly in the hospital sector, to drive future growth [6][9] - The company plans to maintain a strong emphasis on research and development, targeting approximately 10% of sales for R&D initiatives [21] Guidance and Outlook - AngioDynamics raised its fiscal year 2026 net sales guidance to a range of $308 million to $313 million, reflecting growth of 5% to 7% over the previous year [24][25] - The company expects Med Tech net sales to grow 14% to 16%, while Med Device sales are anticipated to remain flat [26] - Adjusted EBITDA is projected to be between $6 million and $10 million, an increase from prior guidance [27]